Optimum duration of adjuvant trastuzumab in treatment of human epidermal growth factor receptor-2 positive early breast cancer: protocol for a network meta-analysis of randomised controlled trials

Optimum duration of adjuvant trastuzumab in treatment of human epidermal growth factor receptor-2 positive early breast cancer: protocol for a network meta-analysis of randomised controlled trials

Bibliographic Details
Main Author: Ting Luo
Format: Article
Language:English
Published: BMJ Publishing Group 2020-11-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/10/11/e035802.full
id doaj-070fb3226eb34a8394ed152c3e2ae2a5
record_format Article
spelling doaj-070fb3226eb34a8394ed152c3e2ae2a52021-06-25T12:40:25ZengBMJ Publishing GroupBMJ Open2044-60552020-11-01101110.1136/bmjopen-2019-035802Optimum duration of adjuvant trastuzumab in treatment of human epidermal growth factor receptor-2 positive early breast cancer: protocol for a network meta-analysis of randomised controlled trialsTing Luo0Department of Endocrinology, the First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, Chinahttps://bmjopen.bmj.com/content/10/11/e035802.full
collection DOAJ
language English
format Article
sources DOAJ
author Ting Luo
spellingShingle Ting Luo
Optimum duration of adjuvant trastuzumab in treatment of human epidermal growth factor receptor-2 positive early breast cancer: protocol for a network meta-analysis of randomised controlled trials
BMJ Open
author_facet Ting Luo
author_sort Ting Luo
title Optimum duration of adjuvant trastuzumab in treatment of human epidermal growth factor receptor-2 positive early breast cancer: protocol for a network meta-analysis of randomised controlled trials
title_short Optimum duration of adjuvant trastuzumab in treatment of human epidermal growth factor receptor-2 positive early breast cancer: protocol for a network meta-analysis of randomised controlled trials
title_full Optimum duration of adjuvant trastuzumab in treatment of human epidermal growth factor receptor-2 positive early breast cancer: protocol for a network meta-analysis of randomised controlled trials
title_fullStr Optimum duration of adjuvant trastuzumab in treatment of human epidermal growth factor receptor-2 positive early breast cancer: protocol for a network meta-analysis of randomised controlled trials
title_full_unstemmed Optimum duration of adjuvant trastuzumab in treatment of human epidermal growth factor receptor-2 positive early breast cancer: protocol for a network meta-analysis of randomised controlled trials
title_sort optimum duration of adjuvant trastuzumab in treatment of human epidermal growth factor receptor-2 positive early breast cancer: protocol for a network meta-analysis of randomised controlled trials
publisher BMJ Publishing Group
series BMJ Open
issn 2044-6055
publishDate 2020-11-01
url https://bmjopen.bmj.com/content/10/11/e035802.full
work_keys_str_mv AT tingluo optimumdurationofadjuvanttrastuzumabintreatmentofhumanepidermalgrowthfactorreceptor2positiveearlybreastcancerprotocolforanetworkmetaanalysisofrandomisedcontrolledtrials
_version_ 1721359640377163776

Similar Items